Azilsartan: eventos adversos em idosos hipertensos (revisão sistemática)

Abstract

Introduction: Hypertension is a highly prevalent multifactorial clinical condition and an important public health problem, since morbidity and mortality are high. Azilsartan medoxomil is a new addition to the class of angiotensin II blockers (ARBs). The hypotensive effect of azilsartan is believed to be superior to that of other ARBs in patients with hypertension. Objectives: To identify and analyze the main adverse events related to the use of azilsartan compared to placebo. Methods: A systematic review was performed with data collected in PubMed, BVS, Embase and CINAL databases, using descriptors and / or their synonyms. We selected randomized controlled trials with hypertensive participants, both sexes and aged 60 years and older. Results: Analysis of the results suggests that there was no statistically significant difference in the occurrence of any adverse events (RR 1.02, 95% CI 0.93 - 1.13) and serious adverse events (RR 0.78, 95% CI 0.25 - 2.38) between azilsartan and placebo.The reduction in the risk of adverse events occurring with azilsartan 40mg compared to placebo was only 0.1%. With azilsartan 80mg, the risk of adverse events occurring was 6% higher compared to placebo. Products: An article entitled “Azilsartan: Adverse Events in Hypertensive Elderly” was developed and a final research report. Conclusion: the products obtained from this study are relevant support instruments in health care, helping in clinical reasoning and decision making